Literature DB >> 16845171

Dynamics of RhoA and ROKalpha translocation in single living cells.

Koji Miyazaki1, Satoshi Komatsu, Mitsuo Ikebe.   

Abstract

The RhoA-binding kinase (ROK) is one of the target kinases of RhoA and is known to play a critical role in regulating cytoskeletal rearrangement in cells. ROK translocates to the plasma membrane fraction; however, the mechanism of the translocation of ROK still remains obscure. To clarify the molecular mechanisms of the translocation of ROK, we co-transfected MDCK cells with cyan fluorescent protein-tagged RhoA and yellow fluorescent protein-tagged ROKalpha, or their variants, and monitored the localization and translocation of the two different fluorescent tagged-molecules in single living cells during epithelial growth factor (EGF) stimulation. Both RhoA (wild-type) and ROKalpha (wild-type) translocated to ruffling membrane with EGF stimulation in several minutes. A ROKalpha mutant, in which Rho-binding ability is disrupted, is unable to translocate to the membrane with RhoA. However, RhoA mutant Q63L/C190R, an active form lacking membrane localization activity, abolished the translocation of wild-type ROKalpha, suggesting that the translocation of RhoA is critical for ROK translocation to the membrane. Another mutant lacking the pleckstrin homology domain failed in translocation as well. On the other hand, it was surprising that the kinase dead mutant succeeded in translocation to the membrane after EGF stimulation. Based on these results, we propose the following ROKalpha translocation mechanism. ROKalpha binds to RhoA in cytosol and translocates to the membrane based on the membrane-targeting ability of active RhoA. After ROKalpha associates with the membrane, the pleckstrin homology domain provides the stability of ROKalpha on the membrane. The activation of enzymatic activity or adenosine triphosphate binding, however, is not directly related to the translocation mechanism, although we found that the membrane association is critical for the activation of the kinase activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845171     DOI: 10.1385/CBB:45:3:243

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  7 in total

1.  TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation.

Authors:  C Seyler; E Duthil-Straub; E Zitron; J Gierten; E P Scholz; R H A Fink; C A Karle; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  RHO GTPase signaling for axon extension: is prenylation important?

Authors:  Filsy Samuel; DiAnna L Hynds
Journal:  Mol Neurobiol       Date:  2010-09-28       Impact factor: 5.590

3.  Membrane and Protein Interactions of the Pleckstrin Homology Domain Superfamily.

Authors:  Marc Lenoir; Irina Kufareva; Ruben Abagyan; Michael Overduin
Journal:  Membranes (Basel)       Date:  2015-10-23

4.  Nucleotide Dependent Switching in Rho GTPase: Conformational Heterogeneity and Competing Molecular Interactions.

Authors:  Amit Kumawat; Suman Chakrabarty; Kiran Kulkarni
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

5.  Actomyosin polarisation through PLC-PKC triggers symmetry breaking of the mouse embryo.

Authors:  Meng Zhu; Chuen Yan Leung; Marta N Shahbazi; Magdalena Zernicka-Goetz
Journal:  Nat Commun       Date:  2017-10-13       Impact factor: 14.919

6.  PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.

Authors:  Zongwei Zhang; Wei Liang; Qiang Luo; Hongtu Hu; Keju Yang; Jijia Hu; Zhaowei Chen; Jili Zhu; Jun Feng; Zijing Zhu; Qingjia Chi; Guohua Ding
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-14       Impact factor: 5.555

7.  Rho GTPase and Shroom direct planar polarized actomyosin contractility during convergent extension.

Authors:  Sérgio de Matos Simões; Avantika Mainieri; Jennifer A Zallen
Journal:  J Cell Biol       Date:  2014-02-17       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.